DI-011 Evaluation of the use of levofloxacin and moxifloxacin in the treatment of pneumonia
Abstract
Background Current recommendations for the management of pneumonia promote two important measures to optimise antibiotic treatment: start sequential treatment early and do not extend antibiotic treatment more than five days in community-acquired pneumonia and eight days in pneumonia related to healthcare. Purpose To analyse the duration of levofloxacin and moxifloxacin treatment in pneumonia and to evaluate the use of sequential treatment. Materials and methods A cross-sectional observational study was performed including all patients admitted for pneumonia to the Pneumology Service of a tertiary hospital, between February–April 2013. The electronic prescribing program was used to identify all patients who started treatment with levofloxacin and moxifloxacin. The diagnosis was confirmed by consulting the electronic medical history. The following variables were analysed: length of treatment in hospital, sequential treatment performed, duration of IV treatment, discharge of patients who had antibiotic treatment and full duration of treatment. Results The total number of patients included in the study was 100. 13 started oral treatment directly with intrahospital treatment lasting 3.92 days. 87 started with IV treatment (82.76% levofloxacin and 17.24% moxifloxacin). 57.47% (50/87) received sequential treatment, with a mean duration of intravenous treatment of 4.04 days. 36 received only inpatient intravenous treatment, with an average duration of 5.67 days. 59% (59/100)…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.